INICIO
Publicaciones
Específicas del Grupo TTD

PUBLICACIONES

1. Abad A, Díaz-Rubio E, Jimeno JM, Rosell R, Villar A, González Larriba JL. Oral Idarubicin in measurable gastric cancer. Am J Clin Oncol. 1989 Feb;12(1):14-6.

2. Alberola V, García-Conde J, Jimeno J, Fernandez-Martos C, Herranz C, Macheng I, Centelles M, Sanchez J. Phase II study with high doses of epirubicin in patients with advanced rectal cancer. Tumori 1990 Oct 31;76(5):503-4.

3. Díaz-Rubio E, Aranda E, Martin M, González-Mancha R, González-Larriba J, Barneto I. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer. 1990;26(6):727-9.

4. Díaz-Rubio E, Jimeno J, Anton A, Aranda E, Sánchez J, Massuti B, Cruz-Hernández J, Carrato A, Martin M, Belón J, González R, Millá A, Sanchiz F, Balaña C, Lizón J, Díaz-Faes J, Alonso A, Navarrete, Sanz Ortiz J, Camps C, del Moral F. A prospective randomized trial of continuous infusion 5-FU vs 50-FU plus cisplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 1992 Feb;15(1):56-60.

5. Díaz-Rubio E, Jimeno J, Camps C, Aranda E, Massuti B, Blanco E, Antón A, Lizón J, González-Larriba JL. Treatment of advanced colorectal cancer with recombinant Interferon alfa and fluorouracil: Activity in liver metastasis. Cancer Invest. 1992;10(4):259-64.

6. Díaz-Rubio E, Jimeno J, Aranda E, Massuti B, Camps C, Cervantes A, Dorta J, Cruz-Hernández JJ, Dominguez S, Antón A, Carrato A, Villar A, Macheng I, Alonso JD, Fernández-Martos C, González R, Fonseca E, Balaña C, Sánchez JJ. Etoposide, epirubicin and cisplatin combination chemotherapy in advancedd gastric cancer: negative impact on the patient clinical outcome. Ann Oncol. 1992 Dec;3(10):861-3.

7. Cervantes A, Villar A, Abad A, Antón A, Belón J, Dorta J, Tres A, Camps C, Fonseca E, Massuti B, Aranda E, Blanco E, García Paredes M, Sánchez JJ, García-Conde J, Díaz-Rubio E. 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A Phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol. 1993 Nov;4(9):753-7.

8. Aranda E, Díaz-Rubio E, Camps C, Fdez-Martos C, Carrato A, Antón A, Cervantes A, Cruz J, Tres A, Belón J, Sanchez J, García-Paredes ML. A phase II study of weekly 48 hours infusion with high-dose Fluorouracil (FU) in colorectal cancer. Cancer Treatment and Update. Ed: P.Banzet, JF Holland, D.Khayat, M.Weil. Springer-Verlag. Paris. 1993: 422-427.

9. Díaz-Rubio E, Aranda E, Camps C, Fernández-Martos C, Carrato A, Antón A, Cervantes A, Tres A, Fonseca E, Belón J, González-Mancha R, Dominguez S, Sánchez JJ. A phase II study of weekly 48-hour infusions with High-Dose Fluorouracil in advanced colorectal cancer: An alternative to biochemical modulation. J Infusional Chemoth. 1994; 4 (1): 58-61

10. Villar A, Aranda E, Massuti B, Belón J, Antón A, Jimeno JM, Candel M, García-Paredes ML, Colajori E. Phase II study with Iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-Fluorouracil. Tumori. 1994 Apr 30;80(2):124-7.

11. Abad A, Massuti, B, Camps C, Font A, Balaña C, Vicent JM, Sánchez JJ. Epirubicin plus a Calmodulin inhibitor (Trifluoperazine) activity in advanced pancreatic adenocarcinoma. Eur J Cancer.1994; 30A(7): 1043

12. Aranda E, Díaz-Rubio E, Camps C, Fernández-Martos C, Carrato A, Antón A, Cervantes A, Fonseca E, Tres A, Belón J. Altas dosis de 5-Fluorouracilo en infusión continua semanal para el tratamiento del carcinoma colorrectal avanzado. Avances en Oncología. Edit. M.González-Barón. Editorial Noesis. Madrid 1995.

13. Aranda E, Cervantes A, Dorta J, Blanco E, Fernández-Martos C, Cruz JJ, Carrato A, González R, García-Conde J, Díaz-Rubio E. A phase II trial of weekly high-dose constant infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer. 1995 Aug 15;76(4):559-63.

14. Aranda E, Cervantes A, Carrato A, Fernandez-Martos C, Antón A, Massuti T, Barreto I, García-Conde J, Barón JM, Díaz-Rubio E. Outpatient weekly high-dose continuous infusion 5-Fluorouracil plus oral Leucovorin in advanced colorectal cancer. A phase II trial. Ann Oncol. 1996 Aug;7(6):581-5.

15. Aranda E, Cervantes A, Carrato A, Antón A, Massuti T, Fernández-Martos C, Díaz-Rubio E. The Spanish experience with high-dose infusional 5-FU in colorectal cancer. J Infus Chemother. 1996;6(3):118-22.

16. Abad A, Navarro M, Sastre J, Marcuello E, Aranda E, Gallén M, Fernández-Martos C, Díaz-Rubio E. A preliminary report of a phase II trial UFT plus oral folinic acid as therapy in colorrectal cancer in older patient (Spanish Group for treatment of digestive tumors. TTD). Oncology. 1997 Sep;11(9 Suppl 10):53-7.

17. Abad A, Massutí B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Antón A, Vicent JM, Dorta J, Garcia de Paredes ML and Ariza A. Seventy-Two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas. Am J Clin Oncol. 1998 Apr;21(2):151-4.

18. Aranda E, Díaz-Rubio E, Cervantes A, Antón A, Carrato A, Massutí T, Tabernero JM, Sastre J, Tres A, Aparicio J, López-Vega JM, Barneto I, and García-Conde J. On behalf of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48 hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol. 1998 Jul;9(7):727-31.

19. Massutí B, Abad A, Carrato A. Adjuvant and palliative treatment of pancreatic cancer. Gastroenterol Hepatol. 1999 Nov;22(9):480-5.

20. Sastre J, Navarro M, Aranda E, Fonseca E, Checa T, Alonso MC, Gallen M, Camps C, Antón A, Díaz-Rubio E. On behalf of the TTD Spanish Cooperative Group. Retrospective evaluation of Toxicity in three different schedules of adjuvant chemoterapy for patients with resected colorectal cancer. Oncol Rep. 1999 Nov-Dec;6(6):1421-4.

21. Díaz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallén M, Marcuello E, Rifá J, Massutí B, Cervantes A, Antón A, Fernández Martos C. UFT plus or minus calcium folinate for metastatic colorrectal cancer in older patients. Oncology. 1999 Jul;13(7 Suppl 3):35-40.

22. Abad A, Aranda E, Navarro M, Carrato A, Sastre J, Gallen M, Marcuello E, Fernández-Martos C, Cervantes A, Antón A, Rivera F, Massutí B, Barreto I, Guillot M and Díaz-Rubio E. For the TTD Spanish Cooperative Group. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer: A trial by the Spanish Group for the Treatment of Gastrointestinal Tumors (TTD). Rev Oncol 2000;2:154-158

23. Aranda E, Antón A, Sastre J, Navarro M, Rivera F, Carrato A, Bretón JJ, Aparicio J, Fernández-Martos C, Díaz-Rubio E. Tegafur and Uracil plus Leucovorin in Advanced Colorectal Cancer: A Phase II trial. Clin Colorectal Cancer. 2001 May;1(1):43-6.

24. Kohne CH, Cunninghan D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5- fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariante analysis of 3825 patients. Ann Oncol 2002 Feb,13 (2):308-17

25. Cervantes A, Díaz-Rubio E, Aranda E. Infusional 5-FU in the treatment of metastatic colorectal cancer: The 48-hour weekly approach. Colorectal Cancer. a clinical guide to therapy. Edited by Bleiberg H, Kemeny N, Rougier P, Wilke H, Editorial Martin Dunitz. 2002

26. Carrato A, Gallego J, Díaz-Rubio E. Oxaliplatin: Results in colorrectal carcinoma. Crit Rev Oncol Hematol. 2002 Oct;44(1):29-44

27. Anton A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, Abad A, Sastre J, Fenandez-Martos C, Gallen M, Diaz-Rubio E, Huarte L, Balcells M. TTD cooperative group. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):639-43.

28. Aranda E, Carrato A, Cervantes A, Sastre J, Gomez MA, Abad A, Masutti B, Ribera F, Marcuello E, Pronk L, Balcells M, Diaz-Rubio E. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. Ann Oncol. 2004 Apr;15(4):559-67.

29. Abad A, Massuti B, Gallego J, Yuste AL, Manzano JL, Carrato A, Anton A, Marfa X, Diaz-Rubio E. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. Anticancer Drugs. 2004 Jun;15(5):469-71.

30. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004 Sep;15(9):1330-8

31. Rougier F, Mitry E, Aranda E, Daniele D, Labianca R, Carrato A. Elderly colorectal cancer patients are undertreated. Eur J Cancer. 2004; 2(7):8-13

32. Carrato A, Aranda E, Gallego Plaza J, Gomez España A. Gastric cancer Neoadjuvant and adjuvant treatments. Advances in gastrointestinal cancer. 2004;2 (3):3-6

33. Aranda E. Grupo de Tratamiento de los Tumores Digestivos, dieciocho años al Servicio de la Oncología. Metástasis óseas. 2004;3 (2):27-29

34. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, and Díaz-Rubio E. Irinotecan in combination with 5-fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer. A Spanish TTD group study. J Clin Oncol. 2005 May 20;23(15):3545-51

35. Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guayar JL, and Diaz-Rubio E. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hr continuous infusion of non-modulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. Clin. Colorectal Cancer. 2005 Mar;4(6):384-9

36. Maurel J, García JL, Bretón JJ, León A, Gallego J, Sánchez P, Fernández Martos C, Galán MªC, Florián J, Dorta FJ, Casinello J, Llanos M, Aranda E, Sastre J, García I, Carrato A. A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD). Clin Transl Oncol. 2005 Dec;7(11):493-8

37. Aranda E. Spanish Cooperative Group for Gastrointestinal Tumor Therapy. Clin Transl Oncol. 2006 Jan;8(1):5-6

38. Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J, and Díaz-Rubio E. On behalf of the TTD Group. Guides for adjuvant treatment of colon cancer. Clin Transl Oncol. 2006 Feb;8(2):98-102.

39. Sastre J, Aranda E, Abad A, Gallego J, Manzano JL, Gómez A, Carrato A, López E, Díaz-Rubio E. UFT in combination with oxaliplatin: a clinical phase I study in patients with advanced or metastatic solid tumors. Anticancer Drugs. 2006 Apr;17(4):417-21.

40. Navarro M, Dotor E, Sánchez-Rovira P, Vega-Villegas Mª E, Cervantes A, García JL, Gallén M, Aranda E. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5.

41. Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, José Reina J, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E. Phase III Study of Capecitabine Plus Oxaliplatin Versus Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007 Jun 4 .

42.Abad A, Figueras J, Valls C, Carrato A, Pardo F, Díaz-Rubio E, Aranda E. Guidelines for the detection and treatment of liver metastases of colorectal cancer .. Clin Transl Oncol. 2007 Nov;9(11):723-30

43.Abad A, Massutí B, Antón A, Vega MªE, Yuste AL, Marcuello E, Manzano J L, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, and Díaz-Rubio E. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol. 2008;47:286-292

44.Eva Martinez-Balibrea, Albert Abad, Enrique Aranda, Javier Sastre, Jose Luis Manzano, Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Jorge Aparicio, Teresa García, Inmaculada Maestu, Anna Martínez-Cardús, Alba Ginés and Elisabet Guino. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer. 2008 Jun;44(9):1229-1237

45.Sastre J., Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, Reina J J, Carrato A, Queralt B, Gómez-España A, González-Flores E, Rivera F, Losa F, García T, Sanchez-Rovira P, Maestu I, Díaz-Rubio E. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Critical Reviews in Oncology/Hematology, Vol 70, issue 2, Pg 134-144. May 2009

46.Enrique Aranda, Manuel Valladares; Mercedes Martinez Villacampa; Manuel Benavides Orgaz; Auxiliadora Gomez; Bartomeu Massutti; Eugenio Marcuello, Manuel Constenla; Juan Carlos Cámara; Alfredo Carrato; Rosario Dueñas; Margarita Reboredo López; Matilde Navarro; Eduardo Díaz-Rubio. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI), as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Annals of Oncology. 2009 Feb;20 (2):251-7

47.F. Rivera, M. Galán, J. Tabernero, A. Cervantes, M. E. Vega-Villegas, J. Gallego, B. Laquente, E. Rodríguez, A. Carrato, P. Escudero, B. Massutí, V. Alonso-Orduña, A.Cardenal, A. Sáenz, J. Giralt,A. Yuste, A. Antón, E. Aranda, On behalf of the Spanish Cooperative Group for Digestive Tumour Therapy (TTD). Phase II Trial of Preoperative Irinotecan-Cisplatin Followed by Concurrent Irinotecan-Cisplatin and Radiotherapy (IC/RT) for Resectable Locally Advanced Gastric and Esophago-gastric Junction Adenocarcinoma. In press International Journal of Radiation Oncology, Biology, Physics

48.M. Majem, M. Navarro, F. Losa, V. Alonso, M.Gallén, F. Rivera, M. Benavides, P. Escudero, E. González, B. Massutí, and E. Aranda. On behalf of the Spanish Cooperative Group for Digestive Tumour Therapy (TTD). Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for resectable locally advanced rectal cancer. Enviado a publicar. Pendiente de valoración

49.J. Sastre, E. Aranda, C. Grávalos, B. Massutí, M. Varella-Garcia, F. Rivera, G. Soler, A. Carrato, JL. Manzano, E. Díaz-Rubio, M. Hidalgo. First line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumour therapy (TTD).Enviado a publicar. Pendiente de valoración